The top five things happening in pharmacy this week in five minutes or less! Hosted by assistant professor of pharmacotherapy and board certified ambulatory care pharmacist, Dr. Elizabeth B. Hearn.
All content for Pharm5 is the property of Elizabeth B. Hearn, PharmD, BCACP and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
The top five things happening in pharmacy this week in five minutes or less! Hosted by assistant professor of pharmacotherapy and board certified ambulatory care pharmacist, Dr. Elizabeth B. Hearn.
Patents ending soon, new antifungal approval, Senate on drug shortages, and more!
Pharm5
4 minutes 37 seconds
2 years ago
Patents ending soon, new antifungal approval, Senate on drug shortages, and more!
This week on Pharm5
Humira biosimilars
Vyvanse, Symbicort, and more losing patents this year
Rezafungin approval
Senate Committee meets on drug shortages
COVID-19 declassified
Connect with us!
Listen to our podcast: Pharm5
Follow us on Twitter: @LizHearnPharmD
References:
Sandoz receives US FDA approval for biosimilar Hyrimoz® (Adalimumab-adaz) high-concentration formulation. Novartis. http://bit.ly/3lBJ1rK. Published March 21, 2023. Accessed March 23, 2023.
Humira [package insert].North Chicago, IL: AbbVie Inc. Accessed March 23, 2023.
Stonehill M. Humira exclusivity expires in 2023: Will biosimilar boom benefit patients or industry? Healio. http://bit.ly/3lzQrvs. Published January 17, 2023. Accessed March 23, 2023.
Amjevita™ (Adalimumab-Atto), first biosimilar to Humira®, now available in the United States. Amgen. http://bit.ly/3Z9gesm. Accessed March 23, 2023.
Kansteiner F, Sagonowsky E, Becker Z, Dunleavy K, Liu A. The top 10 drugs losing us exclusivity in 2023. Fierce Pharma. https://bit.ly/3LGsm0N. Published March 13, 2023. Accessed March 23, 2023.
FDA drug shortages. FDA Drug Shortages. http://bit.ly/3LLEAoY. Accessed March 23, 2023.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022. www.ginasthma.org. Accessed March 23, 2023.
Cidara Therapeutics, Inc. Cidara Therapeutics and Melinta Therapeutics announce FDA approval of Rezzayo™ (rezafungin for injection) for the treatment of
Candidemia and invasive candidiasis. GlobeNewswire News Room. http://bit.ly/40utHMl. Published March 22, 2023. Accessed March 23, 2023.
Thompson GR, Soriano A, Cornely OA, et al. Rezafungin versus Caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): A multicentre, double-blind, double-dummy, randomised phase 3 trial. The Lancet. 2023;401(10370):49-59. doi:10.1016/s0140-6736(22)02324-8
FDA Approves Rezzayo, a Novel Echinocandin. Infectious Disease Special Edition. https://bit.ly/3TAbn2d. Published March 23, 2023. Accessed March 23,
2023.
Gauthier T. Rezafungin (Rezzayo). IDStewardship. http://bit.ly/3LHBn9X. Accessed March 23, 2023.
O'Mary L. Cases of potentially deadly fungus jump 200%: CDC. Medscape. http://bit.ly/40lSRwC. Published March 22, 2023. Accessed March 23, 2023.
Drug shortage health and national security risks: Underlying causes and needed reforms. Committee on Homeland Security & Governmental Affairs. https://bit.ly/3ZdX846. Published March 22, 2023. Accessed March 23, 2023.
Biden signs Bill on COVID origins declassification. AP NEWS. http://bit.ly/3JCsOKJ. Published March 20, 2023. Accessed March 23,
2023.
Pradhan R. End of Covid emergency will usher in changes across the US Health System. Kaiser Health News. http://bit.ly/40xC0H0. Published March 22, 2023. Accessed March 23, 2023.
Pharm5
The top five things happening in pharmacy this week in five minutes or less! Hosted by assistant professor of pharmacotherapy and board certified ambulatory care pharmacist, Dr. Elizabeth B. Hearn.
